Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions
Rhea-AI Summary
Structure Therapeutics (NASDAQ: GPCR) will present multiple clinical and preclinical posters and an oral presentation at the American Diabetes Association 86th Scientific Sessions, June 5–8, 2026, in New Orleans.
Presentations include ACCESS Phase 2b data reporting meaningful weight reductions, a Phase 2 ACCESS II safety/tolerability poster (doses up to 240 mg), a lower‑starting‑dose GI tolerability analysis, and combination and comparative amylin/GLP‑1 preclinical posters.
AI-generated analysis. Not financial advice.
Positive
- ACCESS Phase 2b reports meaningful weight reductions
- Phase 2 ACCESS II evaluated safety/tolerability up to 240 mg
- Combination aleniglipron + ACCG‑2671 showed additional weight loss in obese NHPs
Negative
- Exploration of a lower starting dose signals GI tolerability concerns
News Market Reaction – GPCR
On the day this news was published, GPCR declined 3.90%, reflecting a moderate negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $137M from the company's valuation, bringing the market cap to $3.38B at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
GPCR fell 3.25% while close peers showed mixed moves: PGEN up 3.25%, ELVN up 0.57%, NUVB down 3.27%, AMLX down 1.79%, and TRML flat. Momentum scanner only flagged NTLA, down modestly without news. This pattern points to a stock-specific move rather than a coordinated sector rotation.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 14 | Management change | Positive | +1.9% | Appointment of experienced COO & GC to support Phase 3 execution. |
| Mar 16 | Clinical data update | Positive | +8.7% | Positive Phase 2 ACCESS II topline data for oral GLP-1 agonist aleniglipron. |
| Feb 26 | Earnings and pipeline | Positive | -2.7% | Full-year results, strong weight-loss data and cash runway through end-2028. |
| Dec 17 | Phase 1 initiation | Positive | -2.8% | Start of first-in-human Phase 1 trial for amylin agonist ACCG-2671 in obesity. |
| Dec 11 | Equity offering | Negative | -0.6% | Closing of large upsized equity and pre-funded warrant offering for $747.5M. |
Recent history shows strong positive reactions to major aleniglipron clinical updates, but more mixed or negative reactions around earnings, new programs and financing events.
Over the last six months, GPCR has highlighted steady progress in its obesity pipeline. Positive Phase 2 aleniglipron data in the ACCESS program on Mar 16, 2026 drove an 8.73% gain, while a management addition on Apr 14, 2026 also saw a positive move. Earlier, the company reported strong weight‑loss data and a $1.4 billion cash position with a planned Phase 3 start, initiated Phase 1 for amylin agonist ACCG-2671, and completed a $747.5 million equity raise. Today’s ADA presentation news fits into this ongoing clinical and strategic build‑out.
Regulatory & Risk Context
The company has an effective S-3ASR shelf registration filed on Aug 06, 2025, currently showing 0 recorded usages in the provided data. While this structure allows for future capital raises, no specific capacity or takedown amounts are disclosed here.
Market Pulse Summary
This announcement outlines multiple ADA 2026 presentations that showcase the breadth of Structure’s obesity program, including the ACCESS Phase 2b aleniglipron data, ACCESS II dosing and tolerability, and early combination work with amylin agonist ACCG-2671. In recent months, the company reported strong Phase 2 weight‑loss results and advanced ACCG-2671 into Phase 1. Investors may watch for detailed efficacy, safety and combination findings at the ADA meeting, alongside progress toward planned Phase 3 initiation.
Key Terms
phase 2b medical
phase 2 medical
phase 2 access ii trial medical
glp-1ra medical
glp-1 receptor agonist medical
amylin receptor agonist medical
AI-generated analysis. Not financial advice.
SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced multiple presentations at the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentations include an oral presentation on the ACCESS Phase 2b clinical trial of aleniglipron.
Details of the presentations are as follows:
Title: ACCESS Trial: Dose-Ranging Evaluation of Aleniglipron, an Oral Small Molecule Nonpeptide GLP-1RA, Demonstrates Meaningful Weight Reductions in People Living with Obesity and Overweight
Session: Oral Presentations - Human Studies in Obesity Treatment: Emerging Therapeutic Options and Strategies for Decision-Making (1032-OR)
Speaker: Julio Rosenstock, MD, University of Texas Southwestern Medical Center
Date: Friday, June 5
Time: 12:45 p.m. – 1:00 p.m. CT
Title: Safety, Tolerability, and Efficacy of Aleniglipron in Doses up to 240 mg in People Living with Obesity: The Phase 2 ACCESS II Trial
Session: General Poster Session (2637-P)
Date: Monday, June 8
Time: 12:30 p.m. – 1:30 p.m. CT
Title: Exploring a Lower Starting Dose of Aleniglipron, an Oral Small Molecule GLP-1RA, to Improve GI Tolerability in Obesity: Beyond the ACCESS Trials
Session: Late Breaking Poster Session (3101-LB)
Date: Sunday, June 7
Time: 12:30 p.m. – 1:30 p.m. CT
Title: Combination Treatment of Oral Small Molecule GLP-1 Receptor Agonist Aleniglipron and Small Molecule Amylin Receptor Agonist ACCG-2671 Demonstrated Additional Weight Loss than Monotreatment in Obese NHPs
Session: Late Breaking Poster Session (3061-LB)
Date: Sunday, June 7
Time: 12:30 p.m. – 1:30 p.m. CT
Title: Comparison of Conditioned Taste Avoidance Profiles between GLP-1 Peptides, Amylin Peptides, and Small Molecule Amylin Receptor Agonists
Session: Late Breaking Poster Session (3062-LB)
Date: Sunday, June 7
Time: 12:30 p.m. – 1:30 p.m. CT
Additional information about the ADA 2026 Scientific Sessions is available at the ADA meeting website (American Diabetes Association).
About Structure Therapeutics
Structure Therapeutics is a science-driven clinical-stage biopharmaceutical company focused on discovering and developing innovative oral small molecule treatments for chronic metabolic conditions with significant unmet medical needs. Utilizing its next generation structure-based drug discovery platform, the Company has established a robust GPCR-targeted pipeline, featuring multiple wholly-owned proprietary clinical-stage oral small molecule compounds designed to surpass the scalability limitations of traditional biologic and peptide therapies and be accessible to more people living with obesity around the world. For additional information, please visit www.structuretx.com.
Forward Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including, without limitation, statements concerning: Structure’s expectations around presenting clinical and preclinical data at the ADA meeting, the Company’s future plans and prospects; any expectations regarding the potential benefits, tolerability and safety profile, accessibility, scalability, combinability, capability, efficacy, convenience, expected effects and future application of aleniglipron and any other of the Company’s investigational compounds. In addition, when or if used in this press release, the words and phrases “anticipated,” “believe,” “expect,” “may,” “on track,” “plan,” “potential,” “suggests,” “to be,” “to begin,” “will,” and similar expressions and their variants, as they relate to the Company may identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Although the Company believes the expectations reflected in such forward-looking statements are reasonable, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that actual results, levels of activity, safety, performance or events and circumstances could differ materially from those expressed or implied in the Company’s forward-looking statements due to a variety of risks and uncertainties, which include, without limitation, risks and uncertainties related to potential delays in the commencement, enrollment and completion of the Company’s planned clinical studies; the Company’s ability to advance its clinical and preclinical candidates; the Company’s ability to fund development activities and achieve development goals; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s latest Annual Report on Form 10-K and future reports the Company may file with the SEC from time to time. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.
Investors:
Corey Davis, Ph.D.
LifeSci Advisors, LLC
212-915-2577
cdavis@lifesciadvisors.com
Jun Yoon
Structure Therapeutics Inc.
ir@structuretx.com
Media:
Dan Budwick
1AB
Dan@1abmedia.com
